Xifaxan Related Published Studies
Well-designed clinical trials related to Xifaxan (Rifaximin)
Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. [2008.06.23]
Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study. [2007.10]
Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study. [2007.06.13]
The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. [2006.10.17]
A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. [2006.06]
Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. [2006.05.01]
Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. [2006.04.15]
A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. [2006.02]
Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. [2006]
Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin. [2005.12.01]
An open-label evaluation of rifaximin in the treatment of active Crohn's disease. [2005.08]
Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. [2005.07.01]
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. [2005.06.30]
A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. [2005.05.17]
Rifaximin in patients with lactose intolerance. [2005.05]
Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study. [2005]
Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. [2004.11]
Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. [2004.02]
Therapy of travelers' diarrhea with rifaximin on various continents. [2003.05]
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. [2003.01]
Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. [2003.01]
Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. [2001.12.01]
Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. [2000.05]
Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. [2000.02]
Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-Glucose Breath Test. [2000]
A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of Helicobacter pylori. [1999.05]
Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. [1998.11]
Rifaximin and Helicobacter pylori eradication. [1997.07]
Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. [1997]
Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. [1995.02]
Treatment of pyogenic skin infections with rifaximin cream. [1993.03]
Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. [1993]
Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group. [1992.10]
[Chemotherapeutic prophylaxis in the preparation of the large intestine for surgical interventions: rifaximin P.O. vs. cephalosporin I.V.] [1992.03]
Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. [1991.05]
Well-designed clinical trials possibly related to Xifaxan (Rifaximin)
Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. [2007.07.18]
Role of gut microflora and probiotic effects in the irritable bowel syndrome. [2006.08]
Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. [2006.04]
Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. [2005.05]
Efficacy of mesalazine in the treatment of symptomatic diverticular disease. [2005.03]
Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension. [2004.06]
Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. [2000.08]
Other research related to Xifaxan (Rifaximin)
Rifaximin for the treatment of hepatic encephalopathy. [2008.05.01]
Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. [2008.04]
Rifaximin treatment for symptoms of irritable bowel syndrome. [2008.03]
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. [2008.03]
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. [2008.03]
Rifaximin Treatment for Symptoms of Irritable Bowel Syndrome (March). [2008.02.26]
Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. [2008.01]
The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. [2007.10]
Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. [2007.05]
High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. [2007.04.01]
Interaction between rifaximin and dietary fibre in patients with diverticular disease. [2007.04.01]
Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. [2007.04]
Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. [2007.03.15]
Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. [2007.03]
Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. [2007.02]
Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease. [2007.01.14]
Rifaximin treatment of pathogen-negative travelers' diarrhea. [2007.01]
Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. [2006.12]
Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. [2006.03]
Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. [2006.02.15]
Eradication of Helicobacter pylori: are rifaximin-based regimens effective? [2006]
Safety and tolerability of the antibacterial rifaximin in the treatment of travellers' diarrhoea. [2006]
Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. [2005.04]
Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. [2005.03]
Rifaximin--a novel antimicrobial for enteric infections. [2005.02]
Rifaximin: a new treatment for travelers' diarrhea. [2005.02]
Rifaximin: a nonabsorbed oral antibiotic. [2005.01]
Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract. [2005]
Management of diverticular disease: is there room for rifaximin? [2005]
Treatment of small intestine bacterial overgrowth and related symptoms by rifaximin. [2005]
Management of inflammatory bowel disease: does rifaximin offer any promise? [2005]
Management of hepatic encephalopathy: role of rifaximin. [2005]
Rifaximin in the treatment of infectious diarrhea. [2005]
Rifaximin: in vitro and in vivo antibacterial activity--a review. [2005]
Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. [2005]
Peginterferon-alpha-2a (40kD): a review of its use in the management of patients with chronic hepatitis B. [2005]
Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety. [2005]
Does rifaximin prevent complications of diverticular disease? A retrospective study. [2004.11]
[Clinical and pharmacological aspects of rifaximin, local antibiotic therapy in intestinal disorders] [2004.10.24]
[Evaluation of Helicobacter pylori susceptibility to rifaximin] [2004.08]
Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. [2004.05]
Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. [2003.03]
Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. [2002.07]
[Rifaximin in the treatment of hepatic encephalopathy] [2002.06]
Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. [2002.06]
Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. [2002]
Effects of daily oral administration of rifaximin and neomycin on faecal aerobic flora in rats. [2001.11]
In vitro activity and fecal concentration of rifaximin after oral administration. [2000.08]
Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. [1999.10]
Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach. [1999.01]
Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. [1995.03]
Rifaximin in the treatment of chronic hepatic encephalopathy. [1995]
A prospective study in healthy volunteers of the topical absorption of a 5% rifaximin cream. [1994]
Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. [1994]
Evaluation of the effect of rifaximin in colon diverticular disease by means of lactulose hydrogen breath test. [1994]
In vitro activity of rifaximin, a topical rifamycin derivative, against Chlamydia trachomatis. [1993.02]
Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. [1993.02]
[The rifaximin therapy and prophylaxis of episodes of acute diverticulitis] [1993.01]
Long-term treatment with rifaximin and lactobacilli in post-diverticulitic stenoses of the colon. [1993.01]
|
